30 closest matches · ranked by relevance
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
High Grade Glioma
Primary: Response Rate
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Glioblastoma
Primary: Increase of Interferon Gamma Levels — 0 Participants
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 9.33; 7.62 Months
Glioblastoma
Primary: Progression-Free Survival — 7.71 weeks
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Glioblastoma Multiforme
Primary: Tumor-specific Cytotoxic T-cell Response — 0.496; 0.4836 10^9 cells/L
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
Glioblastoma Multiforme of Brain
Primary: Safety and Tolerability — 19; 2; 2; 2 participants
Glioblastoma
Primary: Concentration of Ixazomib in Tumor Tissue — 7.88; 2.03; 4.17; 2.70 ng/g
Recurrent Glioblastoma
Primary: Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability — 15 percent of participants
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Glioblastoma
Primary: Number of Patients With Adverse Events — 35 Participants
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With…
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Glioblastoma Multiforme
Primary: Percentage of Subjects With Progression-free Survival — 7.5; 15.0 percentage of subjects
Brain Cancer
Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037